Get started
Corbus Pharmaceuticals Holdings, Inc.Corbus Pharmaceuticals Holdings, Inc.Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CRBP chart


Full chart

CRBP upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪203.78 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.82USD
Net income (FY)
‪−44.60 M‬USD
Revenue (FY)
0.00USD
Shares float
‪11.67 M‬
Beta (1Y)
1.72

Employees


Employees (FY)
19
Change (1Y)
−14 −42.42%
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−2.35 M‬USD

About Corbus Pharmaceuticals Holdings, Inc.


Sector
Health Technology
CEO
Yuval Cohen
Headquarters
Norwood
Website
corbuspharma.com
Founded
2009
FIGI
BBG0078PJKQ7
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

CRBP news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where CRBP is featured.

See all sparks 

Frequently Asked Questions


The current price of CRBP is 18.31 USD — it has increased by 6.02% in the past 24 hours. Watch Corbus Pharmaceuticals Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Corbus Pharmaceuticals Holdings, Inc. stocks are traded under the ticker CRBP.
CRBP stock has risen by 1.32% compared to the previous week, the month change is a −12.01% fall, over the last year Corbus Pharmaceuticals Holdings, Inc. has showed a 285.47% increase.
We've gathered analysts' opinions on Corbus Pharmaceuticals Holdings, Inc. future price: according to them, CRBP price has a max estimate of 82.00 USD and a min estimate of 40.00 USD. Watch CRBP chart and read a more detailed Corbus Pharmaceuticals Holdings, Inc. stock forecast: see what analysts think of Corbus Pharmaceuticals Holdings, Inc. and suggest that you do with its stocks.
CRBP reached its all-time high on Oct 10, 2016 with the price of 323.40 USD, and its all-time low was 2.11 USD and was reached on Mar 10, 2023. View more price dynamics on CRBP chart.
See other stocks reaching their highest and lowest prices.
CRBP stock is 14.37% volatile and has beta coefficient of 1.72. Track Corbus Pharmaceuticals Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Corbus Pharmaceuticals Holdings, Inc. there?
Today Corbus Pharmaceuticals Holdings, Inc. has the market capitalization of ‪203.78 M‬, it has decreased by −0.24% over the last week.
Yes, you can track Corbus Pharmaceuticals Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Corbus Pharmaceuticals Holdings, Inc. is going to release the next earnings report on Nov 5, 2024. Keep track of upcoming events with our Earnings Calendar.
CRBP earnings for the last quarter are −0.90 USD per share, whereas the estimation was −1.19 USD resulting in a 24.24% surprise. The estimated earnings for the next quarter are −0.95 USD per share. See more details about Corbus Pharmaceuticals Holdings, Inc. earnings.
Corbus Pharmaceuticals Holdings, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CRBP net income for the last quarter is ‪−10.00 M‬ USD, while the quarter before that showed ‪−6.90 M‬ USD of net income which accounts for −44.91% change. Track more Corbus Pharmaceuticals Holdings, Inc. financial stats to get the full picture.
No, CRBP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 19.00 employees. See our rating of the largest employees — is Corbus Pharmaceuticals Holdings, Inc. on this list?
Like other stocks, CRBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Corbus Pharmaceuticals Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Corbus Pharmaceuticals Holdings, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Corbus Pharmaceuticals Holdings, Inc. stock shows the sell signal. See more of Corbus Pharmaceuticals Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.